Tepotinib hydrochloride is under clinical development by Merck and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II drugs for Colorectal Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tepotinib hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tepotinib hydrochloride overview
Tepotinib hydrochloride (Tepmetko) is anti neoplastic agent. It is formulated as film coated tablets for oral route of administration. Tepmetko is indicated for the treatment of patients with unresectable, advanced or recurrent non-small cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping alterations. Tepmetko is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. Tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. Tepotinib hydrochloride (Tepmetko, MSC-2156119J) is under development for the treatment of advanced gastric cancer and gastroesophageal junction carcinomas (AGC/GEJCs), colorectal cancer, recurrent glioblastoma multiforme (GBM), gliosarcoma, anaplastic astrocytoma, breast cancer, renal cell cancer, gastric cancer, head and neck cancer, other solid tumors, advanced hepatocellular carcinoma, metastatic non-small cell lung cancer and metastatic non-squamous non-small cell lung cancer. The drug candidate is administered orally in the form of film coated tablet and capsule. The drug candidate acts by down-regulating the expression of c-Met. It was also under development for the treatment of metastatic colorectal cancer (mCRC).
Merck, a subsidiary of E. Merck KG, is a science and technology company. It discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis and infertility; and develops liquid crystal mixtures, organic light-emitting diode (OLED) materials, cosmetic active ingredients, pigments for coatings, and high-tech materials. Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. The company serves healthcare, performance materials, and life sciences markets. It has presence in Europe, North America, Asia-Pacific, Latin America and Middle East and Africa. Merck is headquartered in Darmstadt, Hesse, Germany.
For a complete picture of Tepotinib hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.